GeneNews in pact for first personalized medicine center in China

GeneNews (TSX:GEN) has signed a memorandum of understanding with Shanghai Biochip, a leading Chinese engineering center for advanced microarray and gene expression profiling technologies, for a strategic alliance to establish the first Sentinel Centre for Personalized Medicine in China. GeneNews and SBC would jointly establish and manage the Sentinel Centre for Personalized Medicine to co-develop [...]

GeneNews launches ColonSentry in Malaysia

GeneNews (TSX:GEN) has announced the commercial launch of ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia through its GeneNews Diagnostics Sdn. Bhd. subsidiary. “We are excited that GeneNews Diagnostics will now be able to provide the Malaysian population with access to this potentially life-saving colorectal cancer [...]

GeneNews holders okay stock consolidation

Shareholders of GeneNews (TSX:GEN) at a special meeting approved a proposed share consolidation of the basis of one post-consolidation common share for every six pre-consolidation common shares. The timing for implementation of the consolidation will be determined by the company’s board of directors, but will be no later than Jan. 31, 2012. “We believe that [...]

Schizophrenia biomarkers found by GeneNews’ Sentinel Principle

A study using GeneNews’ (TSX:GEN) Sentinel Principle platform technology to identify complex changes in blood gene expression patterns that may be indicative of underlying risk factors for schizophrenia will be published in the American Journal of Medical Genetics Part B and is currently available online. “This study shows that we can identify a gene signature [...]

Rodman sees potential approval of ColonSentry in fourth quarter

In a meeting last week at the Rodman & Renshaw conference with Enzo Biochem (NYSE:ENZ), analyst Yigal Nochomovitz came away with an impression that feedback from New York State regulators “has been favorable” for Enzo’s bid to obtain approval for the GeneNews (TSX:GEN) ColonSentry molecular diagnostic test for assessing a patient’s current risk of having [...]

GeneNews technology able to predict risk of liver cancer for patients with chronic hepatitis

A poster entitled “Biomarkers to predict risk of subsequent hepatocellular cancer in patients with chronic hepatitis,” describing the initial phase of analysis of a 1,600-cohort study using GeneNews’ (TSX:GEN) Sentinel Principle, was presented at the 9th Liver Update 2011 conference in Malaysia. The poster reports on the application of the Sentinel Principle platform technology to [...]

GeneNews closes warrant exercise incentive program

GeneNews (TSX:GEN) has completed an early warrant exercise incentive program and debenture conversion, raising almost $3 million. A total of 74% of eligible warrants were exercised and the company issued 12.8 million common shares and 12.8 million incentive warrants. In addition, holders of 25% of eligible convertible debentures participated in the debenture conversion, resulting in [...]

Personalized medicine is more than targeted therapeutics

That’s a message Enzo Biochem (NYSE:ENZ) wants to get out. “We are positioned extremely well for personalized medicine in the sense that as new immunoassays are recommended by the various professional societies, we are able to move them into the market very quickly because of our broad range of technology and licensure,” David Goldberg, VP [...]

Enzo backs utility of GeneNews test

In an interview with partneringNews, Kevin Krenitsky, President of Enzo Clinical Labs, a unit of Enzo Biochem (NYSE:ENZ), called GeneNews’ (TSX:GEN) ColonSentry pre-screening assay for colorectal cancer risk assessment a “benchmark example for the types of tests Enzo will be advancing.” GeneNews previously licensed ColonSentry to Enzo, which submitted the test for approval to New York [...]

Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

Next Page »